HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2 testing and its predictive utility in anti-HER2 breast cancer therapy
Authors
Keywords
-
Journal
Biomarkers in Medicine
Volume 9, Issue 1, Pages 35-49
Publisher
Future Medicine Ltd
Online
2015-01-21
DOI
10.2217/bmm.14.95
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
- (2014) A Borley et al. BRITISH JOURNAL OF CANCER
- HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab
- (2013) L. Zabaglo et al. ANNALS OF ONCOLOGY
- Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
- (2013) Yi Liu et al. BMC CANCER
- SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
- (2013) Jocelyne Jacquemier et al. BMC CANCER
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
- (2013) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
- (2013) Louis P. Garrison et al. CANCER
- Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831
- (2013) Alvaro Moreno-Aspitia et al. CANCER
- HER2 testing: Current status and future directions
- (2013) Edith A. Perez et al. CANCER TREATMENT REVIEWS
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
- (2013) Wedad M Hanna et al. MODERN PATHOLOGY
- HER2Gene Amplification in Breast Cancer
- (2012) Jane Starczynski et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study
- (2012) V. Georgoulias et al. ANNALS OF ONCOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- High Concordance Between Two Companion Diagnostics Tests
- (2011) Jan Trøst Jørgensen et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HeterogeneousHER2Gene Amplification
- (2011) Alastair I. Bartlett et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
- (2011) M. Bates et al. ANNALS OF ONCOLOGY
- Very high quantitative tumor HER2 content and outcome in early breast cancer
- (2011) H. Joensuu et al. ANNALS OF ONCOLOGY
- Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
- (2011) J Lehmann-Che et al. BRITISH JOURNAL OF CANCER
- HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
- (2011) A. Fabi et al. CLINICAL CANCER RESEARCH
- IGF binding protein-6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis
- (2011) Chunyang Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Quantitative Reverse Transcriptase Polymerase Chain Reaction and the Oncotype DX Test for Assessment of Human Epidermal Growth Factor Receptor 2 Status: Time to Reflect Again?
- (2011) John M.S. Bartlett et al. JOURNAL OF CLINICAL ONCOLOGY
- High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
- (2011) David J. Dabbs et al. JOURNAL OF CLINICAL ONCOLOGY
- Determining TrueHER2Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2Targeted Therapy
- (2011) Chun Hing Tse et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 genetic heterogeneity in breast carcinoma
- (2011) C. Ohlschlegel et al. JOURNAL OF CLINICAL PATHOLOGY
- Evaluation of Intratumoral HER-2 Heterogeneity by Fluorescence In Situ Hybridization in Invasive Breast Cancer: A Single Institution Study
- (2011) Sarah Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
- (2011) Edith A. Perez et al. JNCI-Journal of the National Cancer Institute
- Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
- (2010) Weidong Huang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma
- (2010) Bettina G. Papouchado et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
- (2010) Masakazu Toi et al. BMC CANCER
- Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
- (2010) A. Noske et al. BREAST CANCER RESEARCH AND TREATMENT
- Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
- (2010) Allan Lipton et al. CANCER
- IGFBP2 and IGFBP3 Protein Expressions in Human Breast Cancer: Association with Hormonal Factors and Obesity
- (2010) N. M. Probst-Hensch et al. CLINICAL CANCER RESEARCH
- Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
- (2010) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy
- (2010) J. Zha et al. CLINICAL CANCER RESEARCH
- Determination ofHER2amplification in primary breast cancer using dual-colour chromogenicin situhybridization is comparable to fluorescencein situhybridization: a European multicentre study involving 168 specimens
- (2010) Tomás García-Caballero et al. HISTOPATHOLOGY
- Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients
- (2010) Sabine Riethdorf et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
- (2010) Frederick L. Baehner et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
- (2010) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer
- (2010) M. Cuadros et al. PATHOBIOLOGY
- A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
- (2010) Zaina Sangale et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Emerging Technologies for Assessing HER2 Amplification
- (2009) Frédérique Penault-Llorca et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Microarray-Based Determination of Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Status in Breast Cancer
- (2009) P. Roepman et al. CLINICAL CANCER RESEARCH
- Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast Carcinoma
- (2009) Sejal S. Shah et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens
- (2009) Tommaso Susini et al. GYNECOLOGIC ONCOLOGY
- Molecular Identification and Functional Characterization ofArabidopsis thalianaMitochondrial and Chloroplastic NAD+Carrier Proteins
- (2009) Ferdinando Palmieri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Disease-Free Survival According to Degree ofHER2Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Poor reception?
- (2009) Constantine Alifrangis et al. LANCET
- HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer
- (2008) M. F. Press et al. CLINICAL CANCER RESEARCH
- HER2Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
- (2008) Soonmyung Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
- (2008) V. Guarneri et al. ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search